{
    "Trade/Device Name(s)": [
        "Pointe 360 Glucose Hexokinase Reagent",
        "Glucose Assay",
        "Glucose Test System"
    ],
    "Submitter Information": "Pointe Scientific, Inc.",
    "510(k) Number": "K062118",
    "Predicate Device Reference 510(k) Number(s)": [
        "K953847"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "June 20, 2007",
    "Summary Letter Received Date": "June 22, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Pointe 360 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay",
        "Hexokinase method"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Reagent",
        "System",
        "Analyzer",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Pointe 360 Glucose Hexokinase Reagent for quantitative glucose determination in serum and plasma using the Pointe 360 Analyzer",
    "Indications for Use Summary": "For quantitative determination of glucose in human serum and plasma on the Pointe 360 Analyzer to aid in diagnosis and treatment of diabetes mellitus",
    "fda_folder": "Clinical Chemistry"
}